Pharmaceuticals Analysts discuss the Pulmonary Arterial Hypertension (PAH) landscape and how Merck’s (MRK) Sotatercept PDUFA impacts Gossamer Bio (GOSS) Seralutinib and Keros Therapeutics (KROS) KER-01 on an Analyst/Industry conference call to be held on April 4.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Daiichi Sankyo, Merck announe first patient dosed in REJOICE-Ovarian01 trial
- Merck price target raised to $142 from $139 at Truist
- PDS Biotechnology price target lowered to $5 from $16 at Alliance Global Partners
- Merck: EC approves Keytruda plus chemotherapy to treat NSCLC
- Early notable gainers among liquid option names on March 27th
